ライフサイエンスコーパス: acetylcholinesterase inhibitor

1 tor agonists) and organophosphate miticides (acetylcholinesterase inhibitors).

2 macological intervention using donepezil, an acetylcholinesterase inhibitor.

3 s examined in the presence of ambenonium, an acetylcholinesterase inhibitor.

4 of age, disease severity and baseline use of acetylcholinesterase inhibitors.

5 ves do not have the unwanted side effects of acetylcholinesterase inhibitors.

6 ntration in the neuromuscular junction using acetylcholinesterase inhibitors.

7 after acute and prolonged administration of acetylcholinesterase inhibitors.

8 variety of organophosphate insecticides and acetylcholinesterase inhibitors.

9 observed in 6 of 66 patients who received an acetylcholinesterase inhibitor, 65 of 69 patients who re

10 With the aim of reducing side effects of acetylcholinesterase inhibitors (AChEIs) during symptoma

11 meta-analysis investigating the influence of acetylcholinesterase inhibitors (AChEIs) therapy on nutr

12 sure of GWV to organophosphate and carbamate acetylcholinesterase inhibitors (AChEis), including pyri

13 These drugs, known as acetylcholinesterase inhibitors (AChEIs), were first app

14 behavior; they are slightly resistant to the acetylcholinesterase inhibitor aldicarb, and they exhibi

15 The viable mutants are resistant to the acetylcholinesterase inhibitor aldicarb, indicating that

16 hermore, rab-3 animals were resistant to the acetylcholinesterase inhibitor aldicarb, suggesting that

17 naptic morphology and weak resistance to the acetylcholinesterase inhibitor aldicarb, they are signif

18 ctivity had delayed paralysis induced by the acetylcholinesterase inhibitor aldicarb, whereas mutants

19 muscular junction during lethargus using the acetylcholinesterase inhibitor aldicarb.

20 naling mutants and transgenic animals to the acetylcholinesterase inhibitor aldicarb.

21 ing the sensitivity of intact animals to the acetylcholinesterase inhibitor aldicarb.

22 al defects and show strong resistance to the acetylcholinesterase inhibitor aldicarb.

23 utants also exhibited hypersensitivity to an acetylcholinesterase inhibitor, aldicarb, uncovering def

24 f C. elegans to the paralyzing affects of an acetylcholinesterase inhibitor, aldicarb.

25 Of these, the acetylcholinesterase inhibitor and Alzheimer drug galant

26 nvolves local ACh release, is potentiated by acetylcholinesterase inhibitors and blocked by atropine

27 re also limited by common adverse effects of acetylcholinesterase inhibitors and limited availability

28 Acetylcholinesterase inhibitors and memantine hydrochlor

29 s to examine the safety of NMB reversal with acetylcholinesterase inhibitors and muscarinic anticholi

30 se Research Centre who subsequently received acetylcholinesterase inhibitors and underwent magnetic r

31 thout an aid, had no previous exposure to an acetylcholinesterase inhibitor, and did not have dementi

32 utica, Titusville, NJ) belongs to a class of acetylcholinesterase inhibitors approved for symptomatic

33 Acetylcholinesterase inhibitors are commonly used to tre

34 +/- 6.7 years); 71% of the patients were on acetylcholinesterase inhibitors at baseline; mean Mini-M

35 Rivastigmine was equipotent to the specific acetylcholinesterase inhibitor BW284C51 and more potent

36 enhanced sIPSCs after pretreatment with the acetylcholinesterase inhibitor Bw284c51.

37 y of sacral VF neurons in the presence of an acetylcholinesterase inhibitor can be partially ascribed

38 administered muscarinic receptor agonists or acetylcholinesterase inhibitors can produce antinocicept

39 administered muscarinic receptor agonists or acetylcholinesterase inhibitors can produce effective pa

40 The favorable response to acetylcholinesterase inhibitors, despite a 15-year histo

41 ture was suggested by the fact that when the acetylcholinesterase inhibitor DFP was co-administered w

42 The authors examined the effect of the acetylcholinesterase inhibitor donepezil on magnetic res

43 y improved following a 24-week course of the acetylcholinesterase inhibitor donepezil.

44 milar in normal and lesioned animals and the acetylcholinesterase inhibitor, donepezil (1 mg/kg), pro

45 demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug into brain-penetrabl

46 amates, estrogenic pesticides, and carbamate acetylcholinesterase inhibitors during the second trimes

47 ments of the neonatal rat spinal cord to the acetylcholinesterase inhibitor edrophonium (EDR).

48 The acetylcholinesterase inhibitor eserine reduced Off-EPSC1

49 y a continuous infusion of physostigmine, an acetylcholinesterase inhibitor, for the subsequent 8 sca

50 Acetylcholinesterase inhibitors have also been shown to

51 The beneficial effects of acetylcholinesterase inhibitors, however, are typically

52 ke freely moving male rats, without using an acetylcholinesterase inhibitor in the perfusion medium.

53 ion tomography predict treatment response to acetylcholinesterase inhibitors in patients with dementi

54 ntinuous administration of physostigmine, an acetylcholinesterase inhibitor, increased NMDA receptor

55 AD, and enhancing cholinergic signaling with acetylcholinesterase inhibitors is currently the primary

56 The response to acetylcholinesterase inhibitors is often disappointing.

57 Donepezil, an acetylcholinesterase inhibitor, is an approved drug for

58 carbachol (30-500 pmol per infusion) or the acetylcholinesterase inhibitor neostigmine (7.5-75 pmol

59 s, we microdialyzed a 0.1 mM solution of the acetylcholinesterase inhibitor neostigmine into the L7 l

60 One membrane was perfused with the acetylcholinesterase inhibitor neostigmine, while the ot

61 consisting of the epidural injection of the acetylcholinesterase inhibitor neostigmine.

62 dia, and levels of ACh were increased by the acetylcholinesterase inhibitor neostigmine.

63 d) mice by inhibiting ACh breakdown with the acetylcholinesterase inhibitor neostigmine.

64 p-like state caused by mPRF injection of the acetylcholinesterase inhibitor neostigmine.

65 1000 microM) but was greatly enhanced by the acetylcholinesterase inhibitor physostigmine (1-5 microM

66 The plant-derived acetylcholinesterase inhibitor physostigmine has previou

67 hippocampal (Experiment 2) injections of the acetylcholinesterase inhibitor physostigmine were admini

68 ic activation by systemic application of the acetylcholinesterase inhibitor, physostigmine, resulted

69 treatment with donepezil, a centrally active acetylcholinesterase inhibitor, prevented and reversed o

70 plication of 10 microM neostigmine, a potent acetylcholinesterase inhibitor, prolonged the EPSC decay

71 Treatment with acetylcholinesterase inhibitors resulted in worsened con

72 Acetylcholinesterase inhibitor reversal can cause respir

73 eliorating this cholinergic deficit with the acetylcholinesterase inhibitor rivastigmine would reduce

74 Unlike galantamine, the acetylcholinesterase inhibitors rivastigmine and donepez

75 o acquired myasthenia gravis, treatment with acetylcholinesterase inhibitors should be avoided in DOK

76 vascular side effects usually attendant with acetylcholinesterase inhibitors such as neostigmine.

77 ribed treatments for Alzheimer's disease are acetylcholinesterase inhibitors, such as donepezil and g

78 reviously been shown to confer resistance to acetylcholinesterase inhibitors, suggesting that they ma

79 allosteric muscarinic ligands, including the acetylcholinesterase inhibitor tacrine and the bis-pyrid

80 (arecoline, pilocarpine or oxotremorine), an acetylcholinesterase inhibitor (tacrine or E2020), or ni

81 Galantamine is an acetylcholinesterase inhibitor that also acts as a posit

82 e the efficacy and safety of galantamine, an acetylcholinesterase inhibitor that also acts as an allo

83 Neostigmine is an acetylcholinesterase inhibitor that ameliorates the effe

84 e specific examples of the therapeutics from acetylcholinesterase inhibitors to recent anti-Abeta imm

85 and functional network enhancements with an acetylcholinesterase inhibitor treatment (donepezil) whe

86 are more likely to cognitively improve with acetylcholinesterase inhibitor treatment.

87 nd no evidence that age, disease severity or acetylcholinesterase inhibitor use influenced rate of de

88 ce for influence by age, disease severity or acetylcholinesterase inhibitor use.

89 and Drug Administration-approved reversible acetylcholinesterase inhibitor used to treat mild to mod

90 Use of acetylcholinesterase inhibitors was prohibited.

91 xtended-release physostigmine salicylate, an acetylcholinesterase inhibitor, was evaluated in 850 sub

92 f this study was to test the hypothesis that acetylcholinesterase inhibitors will attenuate the tachy

93 lyzes the hydrolysis of paraoxon and related acetylcholinesterase inhibitors with rate enhancements t